Sab
Founded 2014 · 88 employees on LinkedIn · 1 known investors
Find your way into Sab
111 people in our graph share verified history with the Sab team — schools, employers, funds. One of them is your warm intro.
Scott Pulsipherunlockedknows Eddie J Sullivan · together at Brigham Young University (overlapped)
×2knows the team · via University of Arizona
×5knows the team · via Brigham Young University
knows the team · via Biotechnology Innovation Organization
×3knows the team · via Utah State University
SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates. The company has advanced its lead candidate SAB-142 for Type 1 Diabetes into Phase 2b clinical trials.
Founders & leadership
Sab was founded in 2014 by Eddie J Sullivan.
EJ
Eddie J SullivaninCo-Founder and PresidentEddie J Sullivan is the founder of SAB BIO, a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G therapies using genetically engineered transchromosomic cattle. He brings executive experience in biotechnology with expertise in FDA regulation, vaccines, and infectious diseases.
Investors · 1
Frequently asked questions
- What does Sab do?
- SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates. The company has advanced its lead candidate SAB-142 for Type 1 Diabetes into Phase 2b clinical trials.
- Who founded Sab?
- Sab was founded by Eddie J Sullivan in 2014.
- Who are Sab's investors?
- Sab's investors include JDRF T1D Fund.